October 21, 2009 / 12:59 PM / 10 years ago

UPDATE 1-CombinatoRx: Knee-pain drug effective through 12 months

* Says drug is well-tolerated

* Says no treatment-related adverse events

* Shares up 12 pct in pre-market trade

Oct 21 (Reuters) - Biopharmaceutical company CombinatoRx Inc CRXX.O said its knee osteoarthritis drug, Synavive, continued to show efficacy in a mid-stage 12-month extension trial, sending its shares up 12 percent in pre-market trade.

“Synavive appears to be well-tolerated and efficacious in reducing the signs and symptoms of knee osteoarthritis over a 3 to 12-month period,” interim CEO Robert Forrester said.

In the extension trial for Synavive, there was no treatment-related adverse events, the company said.

Shares of the Cambridge, Massachusetts-based company were up at $1.49 in pre-market trade. They had closed at $1.33 Tuesday on Nasdaq. (Reporting by Anuradha Ramanathan in Bangalore; Editing by Himani Sarkar)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below